Latest Transplantation medicine Stories

HORSHOLM, Denmark, May 23, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it contemplates restructuring the company's operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-Tacro(TM), Veloxis' product candidate for the prevention of organ rejection. It is planned that a discontinuation of other pipeline activities will take place, including early phase research activities. The...

Connie K. Ho for RedOrbit.com Italian doctors recently announced they completed an operation that implanted the smallest artificial heart in a 16-month-old baby boy. He received the device prior to obtaining a permanent organ donation. The operation was completed at Bambino Gesù Hospital, a children’s hospital located in the capital city of Italy. The hospital, first founded in 1869, is now part of the Italian National Healthcare System. The organization focuses on child health, rare...

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels. The research was presented at the Heart Failure Congress 2012, 19-22 May, in Belgrade, Serbia. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. Cancer is the leading cause of death late after heart transplantation. Skin cancer is particularly common, but solid organ cancers including...

(Ivanhoe Newswire) - Cancer is the leading cause of death late after heart transplantation. Now, new research shows that statins, immunomondulatory drugs, may benefit patients beyond their lipid lowering effects. Researchers in Zurich are currently investigating the impact of statin therapy on the occurrence of cancer and death from causes in heart transplantation recipients. They found the increased rate of cancer in heart transplant recipients may be related to the immune suppression of...

Gold Rush Cure Foundation expresses praise for Health Canada's decision to approve the stem cell therapy Prochymal for the treatment of Graft-versus-host disease in children. Laguna Niguel, California (PRWEB) May 19, 2012 The Gold Rush Cure Foundation, a 501 (c)(3) non-profit organization dedicated to raising public awareness and funding for research to eradicate childhood cancer, today expressed praise for Health Canada’s decision to approve the stem cell therapy Prochymal®...

A revolutionary VAD Center integrated process management solution Omaha, NE (PRWEB) May 17, 2012 OTTR™ Chronic Care Solutions, an Omaha-based clinical process management and informatics company, announced that they have signed an agreement with Hartford Hospital to use the OTTR™ Transplant Care Platform. Hartford Hospital is comprehensively using these OTTR Chronic Care Solutions’ modules and interfaces: Heart, Liver, Kidney, VAD, Financial/Insurance, Lab, ADT, SCM, CLP Lab,...

ATLANTA, May 16, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of Hemosphere, Inc. Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. CryoLife will...

RICHMOND, Va., May 15, 2012 /PRNewswire/ -- Donate Life America (DLA) announced today that it has partnered with PGA TOUR golfer and two-time heart transplant recipient Erik Compton on a new educational campaign, "Play Through with Erik Compton," which is supported by Genentech, a member of the Roche Group. "Play Through" aims to raise public awareness of organ donation and urge Americans to consider becoming organ donors. "Last year, Donate Life America achieved a...

ATLANTA, May 15, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has signed a definitive agreement to acquire Hemosphere, Inc., a privately-held medical device company that has developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with...

PRINCETON, N.J., May 14, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012. Soligenix's revenues for the quarter ending March 31, 2012 were $647,418 as compared to $808,005 for the first quarter of 2011. The decrease in revenues was related to a reduction in reimbursable costs from the Company's Orphan Drug Grant...